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ABSTRACT
b-Thalassemia is a genetic disorder caused by
mutations in the b-globin gene. Triplex-forming
oligonucleotides and triplex-forming peptide nucleic
acids (PNAs) have been shown to stimulate recom-
bination in mammalian cells via site-specific bind-
ing and creation of altered helical structures that
provoke DNA repair. However, the use of these
molecules for gene targeting requires homopurine
tracts to facilitate triple helix formation.
Alternatively, to achieve binding to mixed-sequence
target sites for the induced gene correction, we
have used pseudo-complementary PNAs (pcPNAs).
Due to steric hindrance, pcPNAs are unable to
form pcPNA–pcPNA duplexes but can bind to com-
plementary DNA sequences via double duplex-
invasion complexes. We demonstrate here that
pcPNAs, when co-transfected with donor DNA
fragments, can promote single base pair modi-
fication at the start of the second intron of the
beta-globin gene. This was detected by the restora-
tion of proper splicing of transcripts produced
from a green fluorescent protein-beta globin
fusion gene. We also demonstrate that pcPNAs are
effective in stimulating recombination in human
fibroblast cells in a manner dependent on the
nucleotide excision repair factor, XPA. These results
suggest that pcPNAs can be effective tools to
induce heritable, site-specific modification of dis-
ease-related genes in human cells without purine
sequence restriction.
INTRODUCTION
b-Thalassemia, a blood disease linked to defects in the
b-globin gene, is a common genetic disorder that can be
caused by over 200 mutations in the b-globin gene (1).
Many of the mutations responsible for b-thalassemia
involve single base-pair substitutions. Among these,
some of the most frequent cause aberrant splicing of
intron 1 (IVS1-110, IVS1-6 and IVS1-5) or intron 2
(IVS2-1, IVS2-654 and IVS2-745) of the human b-globin
gene (2). Such mutations activate aberrant splice sites in
the introns, leading to the production of aberrantly spliced
mRNA, improper translation and a deﬁciency in b-globin
that ultimately results in b-thalassemia.
In one approach speciﬁc to the thalassemias in which
the genetic defect aﬀects mRNA splicing, antisense
oligonucleotides have been used to block aberrant splice
sites in thalassemic mRNA transcripts (3,4). Nonetheless,
as they do not correct the responsible mutation, there is a
requirement for continued administration of the antisense
molecules to maintain the desired eﬀect.
Gene targeting via homologous recombination (HR)
oﬀers a potential strategy for gene correction. Several
groups have shown that gene correction at a chromosomal
locus can be mediated by donor DNA fragments that are
designed to be homologous to the target gene (diﬀering
only at the bp of the mutation to be corrected) (5,6). Other
studies have shown that site-speciﬁc chromosomal damage
can substantially increase the frequency of HR by exoge-
nous DNA (7). One method to create site-speciﬁc DNA
damage is the use of triplex-forming oligonucleotides
(TFOs) which bind as third strands to homopurine/homo-
pyrimidine sites in duplex DNA in a sequence-speciﬁc
manner (8). The formation of a triple helix creates a
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repair and recombination (9–11). This approach has been
used successfully to stimulate targeted recombination at
chromosomal loci in mammalian cells, with recombina-
tion frequencies of up to 0.5%. Similarly, another class
of DNA-binding molecules, bis-PNAs, which can bind
to homopurine regions to form PNA/DNA/PNA tri-
plexes, with a displaced DNA strand, can create PNA
‘clamps’ that also create a helical distortion that strongly
provokes repair and recombination (12).
However, both of these approaches are limited by the
requirement for a polypurine sequence in the target duplex
to enable triplex formation. To overcome this limitation,
Lohse et al. (13) reported the design of pseudo-comple-
mentary PNAs (pcPNAs), which can bind to duplex
DNA at mixed purine-pyrimidine sequences via double
duplex strand invasion to form four stranded complexes.
To achieve pseudo-complementarity, pcPNAs are synthe-
sized with 2,6-diaminopurine (D) and 2-thiouracil (sU)
nucleobases instead of As and Ts, respectively apart
from natural guanine and cytosine bases. While D and
sU substitutions impede the base pairing between two
mutually pcPNA oligomers (due to steric hindrance),
they do not prevent pcPNAs from binding to the corre-
sponding sequences in DNA carrying natural nucleobases.
As a result, a pair of pcPNAs can pry open a duplex DNA
site via formation of double-duplex invasion complexes.
This novel mode of pcPNA-mediated DNA recognition
substantially extends the range of possible DNA targets
for pcPNAs, since almost any chosen mixed-base site
in duplex DNA can be targeted with pcPNAs (A+T
content  40%).
In work so far, it has been reported that pcPNAs
can block access of T7 RNA polymerase to the corre-
sponding promoter site in vitro thus inhibiting tran-
scription initiation (13). Later it was shown that a pair
of psoralen-conjugated pcPNAs can direct the formation
of targeted psoralen photoadducts on duplex plasmid
DNA in vitro (14) as well as at a chromosomal site in
living cells, leading to the production of site-speciﬁc muta-
tions with high eﬃciency and speciﬁcity (15). These results
suggest the potential of pcPNAs to serve as highly speciﬁc
gene targeting agents in cells.
In the work reported here, we have evaluated the
possibility of using a pair of pcPNAs to stimulate recom-
bination at a chromosomal site in mammalian cells. A
common b-thalassemia mutation occurs at the ﬁrst posi-
tion of intron 2 in the human b-globin gene (designated
IVS2-1). We therefore chose intron 2 of the b-globin gene
as a target for pcPNA binding. We established an assay
for gene correction in which the splicing-defective b-globin
intron 2 is inserted within the green ﬂuorescent protein
(GFP) reporter gene, which in turn was integrated as
a single chromosomal copy in CHO cells. In this assay,
correction of the IVS2-1 mutation is required to allow
GFP expression. We ﬁnd that transfection of cells with
a pair of 13-mer pcPNAs targeting b-globin intron 2, 50
base-pairs downstream of the IVS2-1 mutation can induce
recombination of a 51-mer donor DNA with the target site,
yielding correction of the thalassemia-associated splicing
mutation at frequencies of up to 0.78%. The activity
of the pcPNAs and donor DNAs in gene correction was
enhanced by measures to modify target site accessibility
and to improve oligomer delivery, including synchroni-
zation of the cells in S-phase, treatment of cells with
a histone deacetylase inhibitor, and the use of the
endosome-disrupting agent, chloroquine.
Finally, we demonstrate that pcPNA-induced recom-
bination and gene modiﬁcation is dependent on the
nucleotide excision repair (NER) damage recognition
factor, XPA. Recombination was not detected in human
ﬁbroblast cells deﬁcient in XPA, but was observed in a
cDNA-complemeted line expressing XPA.
These results show that pcPNAs can eﬀectively induce
recombination at mixed-sequence chromosomal target
sites within human b-globin sequences, providing the
foundation for a new therapeutic strategy for modifying
mutations in disease-related human genes.
MATERIALS AND METHODS
Cells
The b-globin intron IVS2-1 (G!A) carrying a thalasse-
mia-associated mutation or its wild-type equivalent
IVS2wt was inserted into the eGFP cDNA sequence of
the pEGFP-N1 plasmid (Clontech, Palo Alto CA),
between nucleotides 105 and 106, by PCR-based homolo-
gous recombination (16), resulting in pGFP/IVS2-1 and
pGFP/IVS2wt, respectively. The HinDIII-NotI fragments
of these plasmids, containing the GFP sequence inter-
rupted by IVS2-1 or IVS2wt construct, were subcloned
into the multiple cloning site of pcDNA5/FRT
(Invitrogen, Carlsbad, CA), and the resulting vectors
were stably transfected into CHO-Flp host cell lines
using the Flp-In System according to manufacturer’s
instructions (Invitrogen, Carlsbad CA). Clones that had
undergone single-copy integration at the expected site
were isolated by selection and conﬁrmed via Southern
blot (data not shown). The resulting CHO-GFP/
IVS2-1
G!A cells and control CHO-GFP/IVS2-1
WT cells
were grown in Ham’s F12 media supplemented with
10% FBS and 2mM L-glutamine.
To study the role of NER in pcPNA-stimulated recom-
bination, two human ﬁbroblast cell lines, the XPA-
deﬁcient XP12RO (homozygous for a nonsense mutation
at Arg207) and its XPA-expressing subline, XP12RO/
CL12 (17) (kind gift from Richard Wood, University of
Pittsburgh Medical School) were used. Cells were main-
tained in RPMI supplemented with 10% heat-inactivated
fetal calf serum, 2mM glutamine and 1% antibiotics
(Invitrogen, Carlsbad, CA).
pcPNAs and oligonucleotides
Boc-protected PNA monomers of 2-thiouracil and 2,
6-diaminopurine were synthesized according to published
methods (13). These monomers were used together with
commercially available Boc-protected G and C PNA
monomers (Applied Biosystems, CA). PNA oligomers
were synthesized on a MBHA resin by standard proce-
dures (18), puriﬁed by RP-HPLC and characterized by
MALDI-TOF mass spectrometry. DNA oligonucleotides
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(TX), using cyanoethyl phosphoramidite chemistry, and
puriﬁed by HPLC. For targeting of the endogenous beta
globin gene, the donor DNA is a 50-mer, single-stranded
end-protected oligonucleotide that is homologous to the
human beta-globin gene but introduces a 6-nucleotide
mutation at the exon 2/intron 2 boundary. Sequences of
oligomers used are presented in Table 1.
Binding assays
To assay for the double duplex invasion complexes, vari-
ous concentrations of pcPNA1 and pcPNA2, as indicated,
were incubated with a desired amount (0.5mg) of
pLSG3T7 in TE buﬀer (pH 7.4) with 10mM KCl for
16h at 378C. The pcPNAs-pLSG3T7 mixtures were then
digested with two restriction enzymes (XhoI and BamHI),
and analyzed by gel electrophoresis in 8% native polya-
crylamide gels (19:1 acrylamide to bisacrylamide) using
TBE buﬀer (90mM Tris pH 8.0, 90mM Boric acid and
2mM EDTA). DNA bands were visualized by silver
staining.
For the GFP-pcPNA-binding assay, plasmid
pBluescript 2–48 containing the target site for the
pcPNA6 and pcPNA7 was generated by annealing the
oligonucleotides 50-GATCATGGTTAAGTTCATGTCA
TA-30 and 50-AATTTATGACATGAACTTAACCAT-30
and cloning them into the BamHI/EcoRI sites of
pBluescriptII-SK (Stratagene, La Jolla, CA). The resulting
plasmid DNA (1mg) containing the binding site was incu-
bated overnight with increasing concentrations of pcPNAs
at 378C in TE buﬀer (pH 7.4) with 10mM KCl. After
incubation to allow plasmid:pcPNA complex formation,
the samples were digested with PvuII to release a 400bp
fragment, and binding was assayed by gel mobility shift as
described above.
Transfection
Total 1 10
6cells in 100ml of media were mixed with
selected pcPNAs (6mM) and GFP-DNA (12mM) oligonu-
cleotides and electroporated in 0.4cm cuvettes using
a Bio-Rad Gene Pulser (280V, 960mFd, Hercules, CA).
Cells were replated in 60mm dishes following electro-
poration and allowed to expand to  90% conﬂuency
(2–3 days). Chloroquine (100mM) or Suberoylanilide
hydroxamic acid (SAHA, 5mM) were added after electro-
poration and media was replaced after 4h. Two days later
as indicated, cells were then visualized via ﬂuorescence
microscopy or analyzed by FACS.
For XP12RO and XP12RO/CL12, 1 10
6cells were
transfected with 4uM beta globin donor DNA (Table 1)
and 0 or 8uM pcPNAs using the Amaxa Nucleofector
according to manufacturer’s instructions (Human ﬁbro-
blast NHDF nucleofection kit, Amaxa Biosystems,
Gaithersburg MD), then placed in RPMI media contain-
ing 10% fetal bovine serum supplemented with G418 at
a ﬁnal concentration of 650ug/mL (Invitrogen, Carlsbad
CA). Cells were harvested 48h post-nucleofection by tryp-
sinization, and then genomic DNA was extracted using
the Wizard Genomic DNA Puriﬁcation kit (Promega,
Madison WI).
Fluorescence microscopy, FACS and live flow cytometry
Cells were visualized using a Zeiss Axiovert 200
(Thornwood, NY) ﬂuorescent microscope at 100  and
200  magniﬁcation. Cells for GFP FACS analysis were
detached by trypsinization, washed once in 1  PBS, and
ﬁxed for at least 2h at 48C in 2% paraformaldehyde in
1  PBS. Prior to FACS, the cells were pelleted and resus-
pended in PBS. Cells were analyzed using a Becton
Dickinson FACS-Calibur ﬂow cytometer (Franklin
Lakes, NJ). Live cell sorting of samples was performed
at the Yale University Cell Sorter Facility using a
Becton Dickinson FACSVantage SE ﬂow cytometer, and
cells were collected in Ham’s F12 media supplemented
with 20% FBS. Collected data were then analyzed using
the FlowJo software (Tree Star Inc., Ashland, OR).
Cell synchronization
Double thymidine addition was used for S phase synchro-
nization. Thymidine was added to 1 10
6cells in Ham’s
F12 media to a ﬁnal concentration of 2mM. Following a
12h incubation period the thymidine-containing medium
was replaced with normal culture medium, and the cells
were grown for an additional 12h to allow exit from S
phase. The cells were grown again in medium containing
2mM thymidine for another 12h to synchronize the cells
at the G1/S border. The arrest was subsequently released
by growing the cells in thymidine-free medium for 4–5h
to allow progression into S phase. Cell cycle proﬁles were
determined by FACS, as discussed above.
RNA isolation and analysis
Total RNA was isolated from expanded GFP-positive
ﬂow-sorted cells using TRIzol Reagent (Invitrogen,
Carlsbad, CA). Messenger RNA transcripts were then
analyzed by reverse transcription-PCR (RT–PCR) on
50ng puriﬁed total RNA with primers pJK115 (50-AGC
AAGGGCGAGGAGCTGTTCACC-30) and pJK118
(50-CACTGCACGCCGTAGGTCAGGGT-30) using the
SuperScript One-Step RT-PCR kit (Invitrogen). The
products were visualized by electrophoresis on a 1.7%
TAE agarose gel. For human cell beta globin RT-PCR,
primers were designed to anneal to exon sequences that
ﬂank IVS2.
Sequence analysis of genomic DNA
Genomic DNA was puriﬁed from expanded GFP-positive
ﬂow-sorted cells using the Wizard Genomic DNA
Puriﬁcation kit (Promega, Madison, WI), and the GFP-
IVS2 region was ampliﬁed using primers pJK115 and
pJK118, as above. The resulting PCR products were gel
puriﬁed and sequenced with forward primer pJK115.
Allele-specific PCR
Gene modiﬁcation in XP12RO and XP12RO/CL12 cells
treated with pcPNAs and beta globin donor DNA was
assayed using allele-speciﬁc PCR, in which the 30 end of
the forward primer corresponds to the wild-type or
mutated sequence as introduced by the donor DNA.
Equal amounts of genomic DNA were subjected to 40
Nucleic Acids Research, 2009,Vol.37, No. 11 3637cycles of 958 for 30s, 628 (mutant allele-speciﬁc primer) or
648 (wild-type primer) for 30s, and 728 for 1min, and the
PCR products were electrophoresed on 1% agarose gels.
RESULTS
pcPNA design and binding motif
The base pairs that are the basis of the pcPNA strategy,
D:T and A:sU, are shown in Figure 1A, along with the
canonical A:T base-pair. Note that, in the apposition of
sU and D, there is potential steric interference between the
thio and amino groups of sU and D, respectively, which
prevents pairing between these analogs. Since sU and
D can bind without steric hindrance to A and T, respec-
tively, pcPNA pairs can bind cognate DNA but not each
other. This property underlies the ability of pcPNAs to
form double duplex strand invasion complexes on
duplex DNA, as shown in Figure 1B.
Initial test on a plasmid target
We ﬁrst investigated the ability of a pair of 10-mer
pcPNAs (pcPNAs1 and pcPNA2; Table 1) to strand
invade into and bind a plasmid target (pSupFLSG3T7)
in vitro. Both of the pcPNAs were modiﬁed at the C and
N-terminus by the addition of lysine residues to provide
positive charges to enhance solubility. The two pcPNAs
were incubated with the plasmid substrate and binding
was assessed by cutting the target region from the plasmid
by restriction enzyme digestion. The binding of the
pcPNAs to the resulting linear fragment was visualized
by gel mobility shift assay; binding of the pcPNA pair
to the target is detected as the band of altered mobility
that appears with increasing concentrations of pcPNAs
(Figure 1C).
We hypothesized that the double duplex strand invasion
complex formed by pcPNAs (Figure 1B) might constitute
a helical alteration suﬃcient to provoke DNA repair
and recombination. This hypothesis was based on an
extrapolation from the activity of TFOs and bis-PNAs,
both of which create altered helical structures that have
been shown to induce recombination in mammalian
cells (12). As a model for gene correction, TFOs and
bis-PNAs are able to stimulate recombination between a
target gene and a DNA donor fragment in mammalian
cells (Figure 1D).
We therefore compared pcPNA1 and pcPNA2 with
TFOs and bis-PNA5 in an assay for induced recombina-
tion in mammalian cells (Table 1 and Figure 1E). In this
assay, we designed each targeting oligomer, including
the pair of pcPNAs, the TFO (AG30) and the bis-PNA
(bis-PNA5) each to bind to a selected site in the supF
reporter gene contained in an SV40-based shuttle vector.
In this vector construct, the supF gene has an inactivating
single base pair mutation which can be corrected by
recombination with a short single stranded oligonucleo-
tide donor. The pcPNAs were designed to bind to a
mixed sequence site 62bp away from the mutation,
whereas the TFO and the bis-PNA were targeted to a
G:C bp rich polypurine site 24bp away from the muta-
tion. The plasmid vector DNA was co-mixed with selected
molecules and the samples were transfected into monkey
COS cells. Two days were allowed for repair/recombina-
tion/replication, and the episomal vector DNA was har-
vested for genetic analysis of the supF gene in indicator
bacteria, as previously described (19). As expected, and
consistent with other published work, the TFO (AG30)
and the bis-PNA5 induced gene correction in the supF
gene at frequencies of 0.14 and 0.21%, respectively.
Interestingly, the pcPNAs appeared to be even more eﬀec-
tive, inducing gene correction by the supF1-donor DNA
at a frequency of 0.65%, more than 7-fold above the activ-
ity of the donor DNA alone. This elevated frequency of
induced recombination produced by the pcPNAs suggests
that these molecules have the potential to form highly
recombinogenic structures when bound to duplex DNA.
A pair of control pcPNAs (pcPNA3 and pcPNA4) with
ﬁve mismatches each to the supF target site were ineﬀec-
tive, showing the sequence speciﬁcity of the process.
Targeted correction of a thalassemia associated muta-
tion in a chromosomal locus
We next sought to test the ability of pcPNAs to induce
gene correction at a chromosomal site. We established
an assay in which the entire second intron of the human
b-globin gene, carrying a thalassemia mutation at position
1 (IVS2-1, G:C to A:T), was inserted within the open
reading frame of the GFP gene to form a fusion gene
designated GFP/IVS2-1
G!A (Figure 2A). This GFP/
IVS2-1
G!A construct was stably transfected into CHO
cells to create a reporter cell line containing a single
copy of the GFP/IVS2-1
G!A gene. The insertion was
directed into a single, pre-deﬁned locus by use of the
CHO-Flp system (20), and the new reporter cell line was
designated as CHO-GFP/IVS2-1
G!A. Single copy inte-
gratation was conﬁrmed by Southern blot (data not
shown). The IVS2-1 mutation disrupts the normal
b-globin splice site, and therefore expression of GFP
requires correction of the IVS2-1 mutation so the
b-globin intron can be spliced out of the GFP mRNA.
We designed a pair of 13-mer pcPNAs, designated as
pcPNA6 and pcPNA7 (Figure 2A and Table 1) to bind
within the b-globin intron at positions 51–64, a distance
of 50bp from the splice site mutation. Binding of
the pcPNAs to the target site in the b-globin intron was
conﬁrmed in a gel mobility shift assay similar to that
described above (Figure 2B). A b-globin/GFP donor
DNA was designed to correct the IVS2-1G:C to A:T
mutation to the wild-type sequence (Figure 2A). This
51-mer contained 25nt of GFP sequence and 26nt of
b-globin sequence.
To test the ability of the pcPNAs to induce gene
correction within b-globin sequences at a chromosomal
site, the CHO-GFP/IVS2-1
G!A cells were transfected
with b-globin/GFP donor DNA alone, b-globin/GFP
donor DNA plus the b-globin pcPNAs (6+7), or
b-globin/GFP donor DNA plus a pair of regular (non-
pseudo-complementary) PNAs of the same sequence
(PNA8 and PNA9). Correction of the IVS2-1G:C to
A:T mutation was detected by the generation of green
3638 Nucleic Acids Research, 2009, Vol. 37,No. 11Figure 1. DNA binding and induced recombination by pcPNAs. (A) Base pairing between 2,6-diaminopurine:thymine and between adenine:
2-thiouracil in comparison to the canonical A:T base pair. Steric hindrance prevents similar base pairing between 2,6-diaminopurine and 2-thiouracil.
(B) Diagram of the double duplex strand invasion complex formed by a pair of pcPNAs on complementary double stranded DNA. (C) Gel mobility
shift assay demonstrating binding of pcPNA1 and pcPNA2 to the target site in the supF gene in a reporter plasmid (psupFLSG3T7). (D) Diagram of
recombination between a target gene and a single stranded donor DNA induced by selected DNA-binding molecules: (i) pcPNAs, (ii) triplex-forming
oligonucleotides (TFOs) and (iii) triplex-forming bis-PNAs. (E) Correction of a point mutation in the supF reporter gene in the shuttle vector,
psupFLSG3T7, mediated by the selected molecules. Plasmid DNA was incubated in vitro with the indicated molecules and the samples were
transfected into monkey COS cells. Two days later, the episomal DNA was isolated for genetic analysis of the supF gene by transformation into
indicator bacteria. Donor DNA indicates a 51-mer single stranded oligonucleotide complementary to the supF gene except for the base pair to be
corrected. Molecules designed to bind to the supF gene include pcPNA1 and pcPNA2, which bind 62bp away from the mutation, the TFO, AG30
and the bis-PNA5, which both bind 24bp away from the mutation to be corrected. Controls include mismatched pcPNA3 and pcPNA4 (CTR-
pcPNAs) and a mismatched DNA oligonucleotide (SCR30). The frequency of gene correction as scored in indicator bacteria is shown. Data
represent at least three replicates in all cases, with standard errors given.
Nucleic Acids Research, 2009,Vol.37, No. 11 3639Figure 2. pcPNA-induced recombination in human b-globin sequences at a chromosomal locus in CHO cells. (A) Schematic illustrating the exper-
imental strategy to study pcPNA-induced recombination. A fusion gene containing the entire second intron of the human b-globin gene, carrying a
thalassemia-associated mutation at position 1 (IVS2-1, G:C to A:T), was inserted within the open reading frame of the GFP gene to form a fusion
gene designated GFP/IVS2-1
G!A. This GFP/IVS2-1
G!A construct was stably transfected into CHO cells to create a reporter cell line containing a
single copy of the GFP/IVS2-1
G!A gene. The IVS2-1 mutation disrupts the normal b-globin splice site, and therefore expression of GFP requires
correction of the IVS2-1 mutation so that the b-globin intron can be spliced out of the GFP mRNA. A pair of 13-mer pcPNAs, designated pcPNA6
and pcPNA7, were designed to bind within the b-globin intron at positions 51–64, a distance of 50bp from the splice site mutation, and to provoke
recombination and gene correction by a co-transfected 51-mer single stranded donor DNA. (B) Gel mobility shift assay to assess binding of
the pcPNAs to the target site in the b-globin intron, as in Figure 2B. (C) Induced recombination in the chromosomal GFP/IVS2-1
G!A gene by
electroporation-mediated transfection with selected molecules: b-globin/GFP donor alone, b-globin/GFP donor plus PNAs (non-pseudo-complemen-
tary PNA8 and PNA9 of the same sequence as pcPNA6 and pcPNA7), or b-globin/GFP donor plus speciﬁc pcPNAs (pcPNA6 and pcPNA7).
Cells were also treated or not with the histone deacetylase inhibitor, SAHA, immediately after electroporation with the indicated molecules.
Table 1. Sequences of PNA and DNA oligomers
pcPNA1 H-Lys-DCGDCSUCDCSU-Lys-NH2
pcPNA2 H-Lys-DGSUGDGSUCGSU-Lys-NH2
pcPNA3 H-Lys-GSUDGDSUCDCSU-Lys-NH2
pcPNA4 H-Lys-DGSUGDSUCSUDC-Lys-NH2
Bis-PNA5 JJJJJTTJJT-O-O-O-TCCTTCCCCC-(Lys)3
pcPNA6 H-Lys-SUDSUGDCDSUGDDCSU-(Lys)4-NH2
pcPNA7 H-Lys-DGSUSUCDSUGSUCDSUD-(Lys)4-NH2
PNA8 H-Lys-TATGACATGAACT-(Lys)4-NH2
PNA9 H-Lys-AGTTCATGTCATA-(Lys)4-NH2
AG30 AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG
SCR30 GGAGGAGTGGAGGGGAGTGAGGGGGGGGGG
supF1 Donor TTCGAACCTTCGAAGTCGATGACGGGAGATTTAGAGTCTGCTCCCTTTGGC
supF2 Donor AGGGAGCAGACTCTAAATCTGCCGTCATCGACTTCGAAGG
b-globin/GFP Donor GTTCAGCGTGTCCGGCGAGGGCGAGGTGAGTCTATGGGACCCTTGATGTTT
b-globin donor AAACATCAAGGGTCCCATAGGTCTATTCTGAAGTTCTCAGGATCCACGTG
PNAs are listed from N to C terminus. D: 2,6-diaminopurine,
SU: 6-thiouracil, O-8-amino-2,6-dioxaoctanoic
acid. DNA sequences are written from 50 to 30.
3640 Nucleic Acids Research, 2009, Vol. 37,No. 11ﬂuorescent cells which were quantiﬁed by FACS or
ﬂuorescent microscopy.
We found that the combination of pcPNAs (6 and 7)
with the b-globin/GFP donor DNA yielded a frequency of
gene correction of 0.012% in a single transfection, 3-fold
above the frequency seen with the b-globin/GFP donor
DNA alone (Figure 2C).
At this stage, we cannot fully explain the diﬀerences in
frequencies between the episomal and chromosomal tar-
gets beyond the obvious diﬀerences in the nature of the
substrates, including accessibility, chromatin structure,
and copy number. In addition to the biological diﬀerences
between episomal and chromosomal loci, we have used
two diﬀerent sets of pcPNAs for these targets. The
reason for this was to optimize the (A+T) content; bind-
ing sites with  40% A:T bp are preferred. To meet this
requirement, we designed and synthesized two diﬀerent
pairs of pcPNAs with slightly diﬀerent lengths for the
episomal and chromosomal targets.
Because previous studies with TFOs have suggested that
the accessibility of chromosomal loci to binding molecules
can vary with cell cycle phase (21) and transcriptional
activity (22), we tested the possibility that modulation
of chromatin/DNA interactions by treatment of cells
with the histone deacetylase (HDAC) inhibitor, SAHA
(an agent currently in clinical trials for cancer therapy),
might increase the ability of the pcPNAs to target the
GFP/IVS2-1
G!A fusion gene. As shown, exposure of
cells to SAHA substantially enhanced the gene correction
frequencies, with the pcPNAs inducing gene correction at
a frequency of 0.17%, a frequency again 3-fold above that
seen with the donor alone under such conditions.
Many factors aﬀect gene correction frequency, such as
the nature of the DNA-binding molecules, their delivery
to the nucleus, the accessibility and structure of the target
region, and possibly the cell cycle. Also, diﬀerent cell lines
and diﬀerent targets may provide for diﬀerent targeting
frequencies. Hence, the frequencies seen in the studies here
are not directly comparable to the frequencies reported
in other work using single-stranded oligonucleotides
alone (6). The point is that whatever the baseline is of
recombination mediated by single-stranded donor DNAs
themselves, the use of pcPNAs can stimulate the level
of recombination.
Note that the pair of unmodiﬁed PNAs (PNA8 and 9),
which have the same cognate sequence as b-globin-
pcPNA6 and b-globin-pcPNA7, respectively, but are com-
plementary to each other, had no eﬀect above that of
the GFP-donor DNA alone (0.004% versus 0.005%).
The inability of this pair to induce gene correction was
expected since they should quench each other by forming
a very stable PNA/PNA duplex. This ﬁnding suggests
that a pair of unmodiﬁed PNAs cannot mediate suﬃcient
strand invasion and target DNA binding to promote
gene correction, a conclusion consistent with the model
that a pair of pcPNAs is necessary to aﬀord suﬃcient
free energy to favor double-duplex invasion complex
formation by binding the two target DNA strands simul-
taneously (13). This demonstrates the importance of the
pseudo-complementarity and provides direct evidence for
pcPNA-induced recombination.
To validate the FACS analysis data (Figure 3A), we
routinely performed ﬂuorescent microscopy to directly
visualize the green cells (Figure 3B). In selected samples
we also used FACS to obtain an enriched population
of green cells produced by treatment of the CHO-GFP/
IVS2-1
G!A cells with the pcPNAs and b-globin/GFP
donor DNA. The RT-PCR analysis of the sorted cells
(Figure 3C, lane 3) was carried out in comparison to
CHO cells containing the GFP gene with the wild-type
beta-globin intron (Figure 3C, lane 1), and with the
CHO cells containing the GFP gene with the mutated
intron Figure 3C, lane 2). Note that the CHO-GFP/
IVS2-1
G!A cells with the mutant splice site have a
larger RT-PCR product consistent with incorrect splicing,
that is, use of an aberrant splice site almost 50nt from the
IVS2-1 site. The CHO-GFP/IVS2 wild type cells with the
wild-type intron yield a smaller RT–PCR product, indic-
ative of correct splicing out of the entire intron. The sorted
cell populations show the correct (smaller) RT-PCR pro-
duct, in keeping with the restoration of the wild-type splice
site sequence at the IVS2-1 position, and consistent with
the observed, acquired GFP expression by microscopy
and FACS.
Finally, as another level of conﬁrmation, genomic DNA
was extracted and sequenced from sorted, GFP-positive
cells that had been in culture for one month, to demon-
strate the presence and persistence of the expected single
base pair change at the genomic level (Figure 3D).
Increased pcPNA-mediated gene correction in cells
synchronized in S-phase
Since manipulation of chromatin by the use of the
HDAC inhibitor, SAHA, yielded an increased frequency
of pcPNA-stimulated gene correction, we tested whether
selectively targeting cells in S-phase might also yield
improved gene correction (23).
The CHO-GFP/IVS2-1
G!A cells were synchronized in
S-phase by double thymidine block (24), yielding a cell
population with 68% of the cells in S-phase. These cells
were transfected with the b-globin-pcPNAs (6+7) plus
b-globin/GFP donor DNA (or b-globin/GFP donor
DNA alone) using electroporation. To attempt further
optimization, replicate samples were also treated either
with the lysomotropic agent, chloroquine (which has
been reported to enhance delivery of PNAs into cells)
(25), or with the HDAC inhibitor, SAHA, which we had
already found to promote increased levels of gene target-
ing in asynchronous cells (Figure 2C).
As shown in Figure 4, S-phase synchronized cells
are more susceptible to gene correction, with a frequency
of 0.19% achieved with the combination of pcPNAs and
b-globin/GFP donor DNA. When chloroquine was
added, the induced gene correction frequency produced
by pcPNAs was further elevated to 0.25%. However, a
greater improvement was seen by the combination of
cell synchronization and HDAC inhibition by SAHA,
yielding a correction frequency of 0.78% in a single treat-
ment, versus 0.29% with donor alone under the same
conditions.
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XPA, in pcPNA-induced recombination
The results above establish that pcPNAs can stimulate
recombination and gene modiﬁcation. It has been shown
earlier that the ability of triplex formation to stimulate
recombination depends on the nucleotide excision repair
pathway and on the damage recognition factor, XPA
(9,10,12). To study whether the NER pathway participates
in pcPNA-induced gene modiﬁcation, we performed the
recombination assay in two human ﬁbroblast cell lines, the
XPA-deﬁcient cell line XP12RO (homozygous for a non-
sense mutation at Arg207) and its XPA-expressing, com-
plemented subline, XP12RO/CL12. Cells were transfected
with 4uM donor DNA (designed to introduce a six
bp sequence change in the beta globin gene at the exon
1/intron 2 border) and 0 or 8uM b-globin-pcPNA6 and
pcPNA7, harvested 48h post-transfection by trypsiniza-
tion, and then genomic DNA was extracted. Gene modi-
ﬁcation was assayed using allele-speciﬁc PCR, in which
the 30 end of the forward primer corresponds to the
wild-type or mutated sequence as introduced by the beta
globin donor DNA. The results reveal that pcPNA and
donor DNA were eﬀective in inducing recombination only
in XPA expressing cells (Figure 5). In the XPA-deﬁcient
cell line, no recombination was detected above the
background (Figure 5).
These ﬁndings suggest that the ability of pcPNAs to
induce recombination depends on the NER factor, XPA,
Figure 3. Conﬁrmation of GFP/IVS2-1
G!A gene correction at the phenotype and genotype level. (A) Sample FACS analysis of CHO-GFP/IVS2-
1
G!A cells treated with pcPNA6 and pcPNA7 plus b-globin/GFP donor DNA. GFP ﬂuorescence is scored on the y-axis, and dots in the upper
sector represent cells expressing GFP. (B) Fluorescence micrograph of pcPNA6 and pcPNA7 and b-globin/GFP donor DNA-treated cells 48h
after transfection, showing GFP-expressing CHO-GFP/IVS2-1
G!A cells in a ﬁeld of predominantly GFP-negative, uncorrected cells. (C) RT–PCR
analysis of RNA harvested from GFP-positive CHO-GFP/IVS2-1
G!A cells that were isolated by FACS. RT–PCR of the correctly spliced mRNA
results in a 209bp product, whereas the IVS2-1 splicing mutation yields a longer mRNA and produces a 256bp RT-PCR product. Lane 1: CHO-
GFP/IVS2
wt cells with wild-type and thus properly spliced intron 2; lane 2: untreated CHO-GFP/IVS2-1
G!A cells; lane 3: CHO-GFP/IVS2-1
G!A
cells treated with pcPNA6 and pcPNA7 and b-globin/GFP donor DNA sorted by FACS to enrich for GFP-positive cells; lane 4: 100bp ladder.
(D) Genomic DNA from GFP-expressing sorted cells was harvested and sequenced to verify genomic modiﬁcation at the target site.
Chromograms are from untreated CHO-GFP/IVS2
wt cells containing the wild-type intron (top), untreated CHO-GFP/IVS2-1
G!A cells with
the IVS2-1GA mutation (middle) and CHO-GFP/IVS2-1
G!A cells treated with pcPNAs and donor DNAs and sorted by FACS for GFP-
expressing cells (bottom).
Figure 4. pcPNA-induced recombination in human b-globin sequences
at a chromosomal locus in S-phase synchronized CHO cells. CHO-
GFP/IVS2-1
G!A cells, synchronized in S-phase, were transfected with
b-globin/GFP donor DNA alone, or with the pcPNA6 and pcPNA7
plus b-globin/GFP donor DNA. Cells were also treated with the endo-
somolytic agent, chloroquine or with the histone deacetylase inhibitor,
SAHA, immediately after electroporation, as indicated. Bar graph
represents data collected from at least three independent experiments,
and with standard error indicated.
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can recognize pcPNA double duplex invasion complexes
as lesions, thereby provoking DNA metabolism to yield
recombinagenic intermediates.
DISCUSSION
The work reported here demonstrates that pcPNAs can be
used to stimulate recombination in mammalian cells.
Initial experiments using plasmid substrates were extended
to a chromosomal target gene consisting of the GFP gene
interrupted by the human b-globin second intron.
Correction of a thalassemia-associated mutation at posi-
tion 1 of b-globin IVS2 was achieved by a combination of
the b-globin-speciﬁc pcPNAs and a 51-mer single stranded
b-globin/GFP donor DNA designed to revert the G:A
mutation to the wild-type A:T sequence and thereby
restore normal splicing. The combination of pcPNA/
donor DNA transfection with cell synchronization in
S-phase and with HDAC inhibition yielded gene correc-
tion frequencies of up to 0.78% in a single treatment.
Correction of the GFP/b-globin fusion gene was
detected at the protein level (green ﬂuorescence in the
treated cells), at the mRNA level (by assaying for wild-
type or mutant splicing products), and at the genomic level
by DNA sequence in FACS-sorted GFP-positive cell
populations. Taken together, the detection of gene correc-
tion in the CHO-GFP/IVS2-1
G!A reporter cell line was
conﬁrmed at all levels.
In our prior work, we had shown that site-speciﬁc
DNA damage mediated by TFOs that bind as third
strands in the major groove can induce recombination at
a chromosomal luciferase reporter gene in mammalian
cells at frequencies up to 0.1% (20). Yet, the use of
TFOs requires the availability of polypurine sequences
due to the involvement of Hoogsteen bonding by the
third strand. The same sequence requirement also restricts
the range of target sites for triplex-forming bis-PNAs.
Importantly, in the work described here, we show that a
pair of pcPNAs can be designed to bind to a mixed
sequence site within the b-globin gene IVS2 and can be
eﬀective in inducing site-speciﬁc recombination in mam-
malian cells at a chromosomal locus. pcPNA binding to
duplex DNA to form a double duplex invasion complex
does not require polypurine regions and needs only 40%
or more A:T bp content, and so there are many potential
pcPNA target sites in all genes.
Recognition of duplex DNA at mixed sequence sites has
been achieved by only two other classes of DNA-binding
molecules, polyamides (26) and modular zinc ﬁnger poly-
peptides (27). Polyamides show high aﬃnity for duplex
DNA in the minor groove, but they have not shown the
ability to mediate targeted genome modiﬁcation in cells.
Zinc ﬁnger polypeptides, when linked to nuclease domains
to form zinc ﬁnger nucleases (ZFNs), can induce recom-
bination events in mammalian cells via the direct creation
of double strand breaks, which promote recombination
(27). Frequencies of gene modiﬁcation achieved with
ZFNs (plus donor DNAs) appear to be about 10-fold
higher than those seen here with pcPNAs (plus donor
DNAs). However, ZFNs are complex proteins that must
be expressed in cells from viral or plasmid vectors and that
can produce variable levels of non-speciﬁc, oﬀ-target
nuclease activity. pcPNAs, in contrast, are relatively
simple, chemically synthesized oligomers which appear
to have favorable toxicity proﬁles.
Nucleotide excision repair is a versatile DNA damage-
removal pathway that plays a critical role in repairing
bulky DNA lesions (28,29). XPA is a key NER factor
responsible for recognizing and verifying altered DNA
conformations, and it is crucial for correct assembly of
the remaining repair machinery around the lesion (30).
Although the exact mechanisms by which these proteins
recognize DNA damage is not understood, damage recog-
nition signals have been proposed, including defects in
the DNA helical structure and modiﬁcation of the
DNA chemistry. The ability of triplex-forming bis-PNAs
and TFOs, to stimulate recombination with donor DNAs
has been shown to be dependent on the nucleotide exci-
sion repair and on XPA in particular. pcPNAs invade
DNA duplex by forming double duplexes invasion com-
plexes and thereby signiﬁcantly altering DNA helical
structure and chemistry. Based on this we hypothesized
that XPA would play a role in the repair of the pcPNA
double duplex invasion structure. Experiments with NER-
deﬁcient human ﬁbroblast cells lacking XPA function and
with a cDNA-corrected, otherwise isogenic subline reveal
that NER is required for production of the recombinants.
Figure 5. Role of the NER pathway in pcPNA-induced recombination. Human ﬁbroblast cell lines, either deﬁcient in XPA and/or complemented
with XPA cDNA, were transfected with pcPNA6 and pcPNA7 plus donor DNAs speciﬁc for beta globin (beta globin donor, designed to introduce a
6bp mutation; Table 1). Gene modiﬁcation was assayed using allele-speciﬁc PCR, in which the 30 end of the forward primer corresponds to the
modiﬁed sequence as introduced by the donor DNA. The gene-speciﬁc wild-type primer ampliﬁes the wild-type allele.
Nucleic Acids Research, 2009,Vol.37, No. 11 3643This result not only is consistent with our previous work
showing that triplex-induced recombination is substan-
tially reduced in human mutant cell lines deﬁcient in
XPA (8,10), but also it demonstrates directly that XPA
is required for the process of pcPNA-induced
recombination.
The work reported here, demonstrates that pcPNAs
having minimum sequence restrictions can eﬀectively
target human b-globin gene sequences and promote cor-
rection of a thalassemia-associated mutation. The work
not only demonstrates targeting of a beta globin construct
in a reporter CHO cell line but also in patient-derived
human XPA-deﬁcient and complemented cells. This
work may provide a basis for a new therapeutic strategy
for hemoglobin disorders.
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